Plyukhova, A.A.; Budzinskaya, M.V.; Starostin, K.M.; Rejdak, R.; Bucolo, C.; Reibaldi, M.; Toro, M.D.
Comparative Safety of Bevacizumab, Ranibizumab, and Aflibercept for Treatment of Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Network Meta-Analysis of Direct Comparative Studies. J. Clin. Med. 2020, 9, 1522.
https://doi.org/10.3390/jcm9051522
AMA Style
Plyukhova AA, Budzinskaya MV, Starostin KM, Rejdak R, Bucolo C, Reibaldi M, Toro MD.
Comparative Safety of Bevacizumab, Ranibizumab, and Aflibercept for Treatment of Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Network Meta-Analysis of Direct Comparative Studies. Journal of Clinical Medicine. 2020; 9(5):1522.
https://doi.org/10.3390/jcm9051522
Chicago/Turabian Style
Plyukhova, Anna A., Maria V. Budzinskaya, Kirill M. Starostin, Robert Rejdak, Claudio Bucolo, Michele Reibaldi, and Mario D. Toro.
2020. "Comparative Safety of Bevacizumab, Ranibizumab, and Aflibercept for Treatment of Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Network Meta-Analysis of Direct Comparative Studies" Journal of Clinical Medicine 9, no. 5: 1522.
https://doi.org/10.3390/jcm9051522
APA Style
Plyukhova, A. A., Budzinskaya, M. V., Starostin, K. M., Rejdak, R., Bucolo, C., Reibaldi, M., & Toro, M. D.
(2020). Comparative Safety of Bevacizumab, Ranibizumab, and Aflibercept for Treatment of Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Network Meta-Analysis of Direct Comparative Studies. Journal of Clinical Medicine, 9(5), 1522.
https://doi.org/10.3390/jcm9051522